Onasemnogene Abeparvovec (Zolgensma)
One-time SMN1 gene replacement therapy for spinal muscular atrophy in eligible pediatric patients.
What is Onasemnogene Abeparvovec (Zolgensma)?
What it targets
SMN1 gene replacement via AAV9 vector
Who it may help
Infants and young children with confirmed bi-allelic SMN1 mutations
Why testing matters
SMN1 genetic testing, SMN2 copy number, anti-AAV9 antibody level, liver function, and blood counts required before treatment
Conditions treated with Onasemnogene Abeparvovec
Zolgensma is approved for specific SMA populations. Eligibility depends on confirmed genetic diagnosis, age, antibody status, and specialist assessment.
| Spinal Muscular Atrophy (SMA) | The primary indication. For patients with confirmed bi-allelic SMN1 gene mutations. |
| Infantile-onset SMA (Type 1) | The most severe form. Zolgensma may improve survival and motor outcomes when given early. |
| Pre-symptomatic SMA | Diagnosed via newborn screening or family genetic testing before symptoms develop. |
| SMA Type 2 (selected patients) | Some approvals cover type 2 SMA depending on country, age, and specialist criteria. |
Who may be eligible for Zolgensma?
Not every child with SMA qualifies. Eligibility is determined by a specialist based on genetic test results, age, weight, clinical condition, and safety testing.
- Confirmed bi-allelic SMN1 gene mutation on genetic testing
- Within the approved age or weight range in the relevant country
- Anti-AAV9 antibody level below the threshold required for safe administration
- Acceptable liver function tests before infusion
- Platelet count and complete blood count within acceptable range
- No active serious infection or uncontrolled fever at time of infusion
- Specialist assessment confirms gene therapy is appropriate for this patient
- Family has received full counselling on benefits, risks, cost, and alternatives
- Not suitable if outside the approved age or weight range in their country
- Not suitable if anti-AAV9 antibody levels exceed the safety threshold
- Not suitable with active liver disease or significantly abnormal liver function
- Not suitable with active serious infection or uncontrolled illness at time of planned infusion
- Not suitable if the patient has already received another AAV-based gene therapy
How does Onasemnogene Abeparvovec work?
- The genetic defect in SMA
- The AAV9 gene delivery vector
- Gene delivery and SMN protein production
- Why early treatment matters
Tests required before Zolgensma treatment
A comprehensive panel of tests is mandatory before infusion to confirm eligibility and assess safety. Results guide timing, dosing, and the corticosteroid plan.
| SMN1 genetic testing | Confirms bi-allelic SMN1 mutation — the primary eligibility requirement. |
| SMN2 copy number testing | Helps predict disease severity and inform clinical decision-making. |
| Anti-AAV9 antibody testing | High antibody levels may exclude the patient; result must be within threshold. |
| Liver function tests (LFT) | Baseline liver health assessment; critical given risk of post-infusion hepatotoxicity. |
| Complete blood count (CBC) | Platelet count and overall blood health assessed before infusion. |
| Troponin-I | Cardiac biomarker tested at baseline and monitored after infusion. |
| Kidney function tests | Baseline renal function and blood chemistry profile. |
| Clinical assessment | Neurology, respiratory, feeding, and weight assessment. Weight determines dosing. |
How is Onasemnogene Abeparvovec given?
Zolgensma is a one-time intravenous infusion given at a specialized hospital or gene therapy centre. The child must be pre-treated with corticosteroids and monitored closely before, during, and after infusion.
| Route of administration | Intravenous (IV) infusion — administered through a peripheral or central line. |
| Dose calculation | Dose is based on the child's body weight at the time of infusion. Confirmed by the treating team. |
| Corticosteroid pre-treatment | Systemic corticosteroids (typically prednisolone) are started before and continued after infusion to reduce liver inflammation risk. |
| Number of doses | One time only. Repeat administration has not been evaluated and is not recommended. |
| Infusion setting | Must be given only at centres experienced in SMA, gene therapy, pediatric critical care, and infusion monitoring. |
| Infusion duration | Infusion typically takes approximately 60 minutes. Extended observation follows in hospital. |
| Post-infusion monitoring | Liver function, platelet count, and troponin-I monitored weekly for the first month, then regularly for months afterward. |
| Duration of corticosteroid cover | Steroid taper typically continues for 30 or more days after infusion per protocol. Team adjusts based on liver enzyme trends. |
Clinical evidence and potential benefits
Zolgensma has demonstrated meaningful clinical benefit in selected infants with SMA, particularly when given early. Results from the STR1VE and SPR1NT clinical programs provide the primary evidence base.
| Improved survival in Type 1 SMA | In the STR1VE trial, the majority of treated infants were alive and free of permanent ventilation at 14 months — a significantly better outcome than the natural history of untreated severe SMA. |
| Motor milestone achievement | Treated infants achieved milestones including head control, sitting without support, and in some cases standing and walking — outcomes rarely seen with untreated infantile SMA. |
| Pre-symptomatic treatment outcomes | In the SPR1NT program, children treated before symptom onset achieved motor milestones consistent with normal development in a substantial proportion of cases. |
| One-time treatment | Unlike nusinersen (intrathecal injections) or risdiplam (daily oral), Zolgensma is a single infusion — eliminating the need for ongoing chronic SMA-specific drug therapy in some patients. |
| Early intervention advantage | Benefits are greatest when treatment is given early, before significant motor neuron loss. Newborn screening and early genetic diagnosis are key to maximising outcomes. |
Individual responses vary. Benefits are greatest when treatment is given early. These represent published clinical data — your child's outcome will depend on their specific disease stage, SMN2 copy number, and timing of treatment.
Side effects of Onasemnogene Abeparvovec
Zolgensma is not chemotherapy — its side effect profile is specific to gene therapy and immune activation. Most children tolerate the infusion, but serious risks require close monitoring and corticosteroid management.
| Elevated liver enzymes | Very common. Liver enzymes typically rise in the first weeks after infusion. Managed with corticosteroids and resolved in most cases with monitoring. |
| Low platelet count (thrombocytopenia) | Can develop post-infusion. Platelet counts are monitored regularly. May require dose adjustment of corticosteroids or additional intervention. |
| Vomiting | Common around the time of infusion. Usually transient. |
| Fever | May occur post-infusion as part of an immune response to the viral vector. |
| Elevated troponin-I | Cardiac biomarker elevation reported post-infusion. Most cases are asymptomatic and resolve. Requires monitoring. |
| Acute liver injury | Serious risk. Can progress to liver failure in rare cases. Requires immediate medical attention if signs of liver dysfunction appear. |
| Thrombotic microangiopathy (TMA) | Rare but serious. Involves small blood vessel damage. Monitored through blood tests post-infusion. |
| Immune reaction to AAV9 vector | The body's immune system may react to the viral vector. Corticosteroids are used prophylactically to reduce this risk. |
| Temporary inflammation | Generalized inflammatory response may occur. Part of the expected immune reaction to gene therapy. |
| Abnormal blood test results | Multiple lab value changes (enzymes, counts, biomarkers) are expected and monitored as part of the post-infusion protocol. |
Contact your medical team immediately if the child develops:
- Yellow skin or eyes, dark urine, pale stools — signs of liver injury
- Unusual bruising, small red or purple spots on skin, or prolonged bleeding
- Reduced feeding, persistent vomiting, or unusual drowsiness or lethargy
- Difficulty breathing or increased work of breathing not explained by SMA
- Persistent fever that does not resolve or worsens after infusion
- Reduced urine output or swelling in the limbs
Safety precautions before and after Zolgensma
Always inform the treating team about the child's full medical history, all current medications, recent vaccinations, and any planned procedures.
- Tell the specialist if the child has any active infection or fever — infusion must be deferred until the child is well
- Inform the team of any previous SMA treatment including nusinersen or risdiplam
- Anti-AAV9 antibody status must be confirmed — high levels may exclude the child from treatment
- Live vaccines should generally not be given around the time of infusion — discuss the vaccination schedule with the team
- Corticosteroid therapy is mandatory — the team will provide a detailed steroid plan before the infusion date
- Do not stop corticosteroids without doctor guidance even if liver enzymes appear normal
- Inform the team of any planned surgery, procedures, or immunizations in the weeks around infusion
- Liver function monitoring must continue as scheduled — do not miss blood test appointments after infusion
Onasemnogene Abeparvovec with other SMA treatments
The question of whether to use Zolgensma alone, before, after, or together with other SMA medications is complex. There is no universal recommendation — the decision depends on the individual child's age, disease stage, response, and country of treatment.
| Zolgensma + nusinersen (Spinraza) | Some patients have received both. Whether to continue nusinersen after Zolgensma is a specialist decision. No universal guideline exists — depends on response and motor neuron preservation. |
| Zolgensma + risdiplam (Evrysdi) | Some centres have used risdiplam before or after Zolgensma. Sequential or concurrent use is not standard but may be considered in selected cases under specialist guidance. |
| Supportive therapies | Physiotherapy, respiratory support, nutritional support, and orthopedic care remain important alongside gene therapy and are not replaced by Zolgensma. |
| If Zolgensma is not suitable | Children who do not qualify for Zolgensma may still benefit from nusinersen or risdiplam as standalone treatments for SMA. |
If Onasemnogene Abeparvovec does not provide adequate benefit
Zolgensma may not produce the hoped-for motor improvement in all children. Several factors can limit the response, and the treating team will reassess and discuss alternatives.
| Late treatment — motor neuron loss already advanced | The most common reason for limited response. Motor neurons lost before treatment cannot be recovered. Early diagnosis is critical to maximising outcomes. |
| Insufficient SMN2 backup copies | Children with fewer SMN2 copies have less natural SMN protein backup. Response may be more limited despite successful gene delivery. |
| High anti-AAV9 antibody titre at baseline | Elevated antibody levels may reduce gene delivery efficiency. This is screened for before treatment. |
| Variable gene expression over time | Long-term durability of SMN1 gene expression from Zolgensma is still being studied. Very long-term data beyond 5–7 years remains limited as of 2026. |
| Next steps if response is limited | The specialist may consider nusinersen or risdiplam, intensified physiotherapy and rehabilitation, respiratory and nutritional support, and clinical trial eligibility. |
Cost of Onasemnogene Abeparvovec globally
Zolgensma is among the most expensive therapies in the world. Total cost includes the drug itself, hospitalization, monitoring, steroid therapy, pre-treatment testing, and long-term follow-up.
| United States | List price approximately USD 2.1 million per dose. Insurance, Medicaid, or Novartis outcomes-based payment programs may apply. Patient assistance programs available for eligible families. |
| Europe | Reimbursed in some EU countries under national health systems with strict eligibility criteria. Self-pay access is rare due to the cost. Named-patient programs exist in select markets. |
| India | Not routinely approved for commercial supply as of 2026. Some families have accessed it through special import permissions. Costs include drug, logistics, hospitalization, monitoring, and ICU support. |
| China | A domestic gene therapy for SMA (CanSino Biologics / Roctavian-related programs) has been in development. Zolgensma availability through international access varies. Specialist inquiry recommended. |
| Other Asian / Middle Eastern markets | Access is typically through named-patient pathways or participation in registry programs. Costs are substantial. Insurance coverage is limited in most countries outside the USA and select EU states. |
| Additional costs to budget for | Genetic testing, anti-AAV9 antibody testing, LFTs, CBC and troponin monitoring, corticosteroid therapy, hospital stays, physiotherapy, respiratory care, and long-term neurology follow-up. |
Global availability of Onasemnogene Abeparvovec
Zolgensma is approved in major markets for defined SMA populations. Practical access varies significantly by country, hospital capability, payer coverage, and import regulations.
United States
FDA-approved for patients under 2 years with bi-allelic SMN1 mutations. Available at specialized neuromuscular and gene therapy centres. Patient assistance and outcomes-based payment programs available.
European Union
EMA-authorized for SMA with bi-allelic SMN1 mutations. Reimbursement varies by member state. Available at approved gene therapy centres in Germany, France, UK, Italy, and others.
United Kingdom
MHRA approval. NHS England has commissioned Zolgensma for eligible SMA patients through specialist centres. Strict eligibility criteria apply — assessed by the NHS England SMA team.
India
Not commercially approved as of 2026. Some families have pursued special import permission under compassionate use or named-patient pathways through CDSCO. Requires specialist and regulatory coordination.
China
Zolgensma (Novartis) access is limited. Domestic gene therapy programs for SMA are under development. Families may explore international access through cross-border care coordination.
South Korea / Japan
Approved in Japan and South Korea for specific SMA populations. Access through approved hospital centres. Reimbursement conditions and eligibility criteria apply in each country.
Onasemnogene Abeparvovec in current clinical research
Research continues to expand the evidence base for Zolgensma across SMA subtypes, age groups, and combination strategies.
| Long-term follow-up studies | Ongoing registries and follow-up programs track motor development, SMN protein expression durability, and safety in children treated in the STR1VE and SPR1NT programs. |
| Older age groups and higher body weights | Studies exploring whether gene therapy can benefit children beyond the current approved age and weight thresholds, particularly in SMA types 2 and 3. |
| Combination with SMN-splicing agents | Investigational approaches studying Zolgensma together with nusinersen or risdiplam to assess additive benefit and safety. |
| Intrathecal delivery research | Research into intrathecal routes of AAV gene therapy delivery for SMA, potentially expanding options for older or heavier patients where IV delivery efficiency may differ. |
| Next-generation SMA gene therapies | Second-generation AAV vectors with improved CNS targeting and reduced systemic liver exposure are in early clinical development for SMA and related neuromuscular conditions. |
Your child's treatment journey with Onasemnogene Abeparvovec
Diagnosis — genetic testing confirms SMA
SMA specialist evaluation
Pre-treatment safety testing
Family counselling and consent
Corticosteroid initiation
Zolgensma infusion (one-time)
Intensive post-infusion monitoring
Ongoing neurodevelopmental and SMA follow-up
Questions to ask the specialist about Onasemnogene Abeparvovec
- Has SMA been confirmed by SMN1 genetic testing, and what is the SMN2 copy number?
- Is my child's anti-AAV9 antibody level within the range needed for Zolgensma?
- What are the realistic expected benefits for my child given the current disease stage?
- What is the corticosteroid plan and what side effects should we watch for?
- What monitoring will be needed after the infusion and for how long?
- Should my child also receive nusinersen or risdiplam, or should Zolgensma be given alone?
- Is Zolgensma available in this country, and what does the full cost include?
- What happens if the motor response is limited or symptoms progress after treatment?
How CancerFax supports families exploring Zolgensma
CancerFax helps families navigate access to advanced therapies including gene therapy for SMA — from report review and specialist connection to cost and international care coordination.
| Medical report review | Upload your child's genetic reports, anti-AAV9 antibody results, liver function tests, and neurology assessments — our team will review and explain what they mean for Zolgensma eligibility. |
| SMA specialist connection | We connect families with pediatric neurologists and SMA specialists experienced in gene therapy evaluation in India, China, UAE, Singapore, Europe, and internationally. |
| Second opinion coordination | If you want a second specialist opinion on whether Zolgensma is appropriate for your child — or whether nusinersen or risdiplam is a better fit — CancerFax can arrange this. |
| Access and import pathway guidance | For families in countries where Zolgensma is not commercially approved, CancerFax can help explore named-patient import options, compassionate use pathways, or clinical trial access. |
| Cost and funding navigation | We help families understand the full cost picture, identify patient assistance programs, outcomes-based payment options, and insurance reimbursement possibilities. |
| International treatment coordination | For families travelling internationally for Zolgensma or post-treatment follow-up, CancerFax manages specialist appointments, logistics, hospital access, and care coordination. |
Frequently asked questions about Onasemnogene Abeparvovec (Zolgensma)
Common questions from families and caregivers navigating SMA treatment options
Onasemnogene abeparvovec, sold as Zolgensma, is a one-time gene therapy that delivers a working copy of the SMN1 gene directly into the body using a viral vector. Unlike nusinersen (Spinraza) or risdiplam (Evrysdi), which require ongoing doses to increase SMN protein, Zolgensma is a single infusion intended to address the underlying genetic cause of SMA. It does not cure SMA but may provide lasting benefit when given early.
In the United States, Zolgensma is approved for children under 2 years of age with SMA caused by bi-allelic mutations in the SMN1 gene. In Europe, the EMA has authorized it for patients with SMA regardless of weight, subject to specialist criteria. Eligibility depends on anti-AAV9 antibody levels, liver function, infection status, and overall health. Your child's neurologist or SMA specialist will determine suitability.
Some patients have received Zolgensma after prior nusinersen or risdiplam, and some continue one of these treatments afterward. Whether to switch, combine, or sequence SMA therapies is a complex specialist decision that depends on the child's age, disease stage, response to prior therapy, and local approval. There is no universal consensus — your SMA specialist will advise based on your child's individual situation.
The most serious risks include severe bleeding, gastrointestinal perforation, fistula formation, blood clots, stroke, heart attack, poor wound healing, and a rare brain condition called reversible posterior leukoencephalopathy syndrome. High blood pressure and protein in the urine are common and need monitoring at every cycle. Your oncologist will explain which of these risks apply to your situation and how they will be monitored. Always report unusual headache, chest pain, sudden weakness, heavy bleeding, or severe abdominal pain to your care team immediately.
Zolgensma is one of the most expensive therapies globally. In the United States, the list price has been reported at approximately USD 2 million, though insurance, Medicaid, or patient assistance programs may significantly reduce out-of-pocket cost. Novartis offers an outcomes-based payment program and a patient assistance program in some markets. Costs in other countries depend on local approval, hospital, import process, and insurance. CancerFax can help families explore access and cost navigation options.
Yes — follow-up is essential. After the infusion, children require regular liver function tests, platelet counts, troponin-I measurements, and complete blood counts, often for weeks to months. Steroid treatment continues for a defined period. Neurology, respiratory, feeding, physiotherapy, and rehabilitation follow-up continue long-term regardless of initial response. Some children benefit significantly; others may require additional SMA-directed treatment or ongoing supportive care.
As of 2026, Zolgensma is approved in the United States and European Union for defined SMA populations. Availability in India, China, and other Asian countries varies significantly — some patients have accessed it through named-patient import pathways or clinical programs. Routine availability is not guaranteed in all countries. CancerFax can help families check practical access options based on their location and the child's clinical profile.
No — repeat administration of Zolgensma has not been evaluated and is not recommended. It is a one-time gene therapy. Additionally, most patients who have received one dose will develop immunity to the AAV9 vector, which would prevent a second dose from working. If the first infusion does not produce the hoped-for benefit, the SMA specialist will discuss other treatment options including nusinersen, risdiplam, or clinical trials.